Skip to content

Injectable Bulking Agent Needle Guide

Injectable Bulking Agent Needle Guide

Status
Terminated
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00763711
Acronym
NG
Enrollment
17
Registered
2008-10-01
Start date
2008-06-30
Completion date
2009-11-30
Last updated
2012-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrinsic Sphincter Deficiency, Urinary Incontinence

Keywords

Urinary Incontinence, ISD

Brief summary

The purpose of this study is to evaluate the use of the Needle Guide as an assist in properly guiding an injection needle into the appropriate tissue plane during an injectable bulking agent procedure in women using a FDA approved injectable bulking agent. The injectable bulking agent will be Durasphere EXP.

Interventions

DEVICENeedle Guided Periurethral Injection

Bulking Agent injection using a needle guide

Sponsors

Carbon Medical Technologies
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

Individuals satisfying the Indications and Contraindications criteria in the Durasphere EXP Directions for Use may participate.

Design outcomes

Primary

MeasureTime frame
to evaluate the consistency of the location of the injection site and resulting location of bulking effectat procedure
Safety will be demonstrated through an analysis of morbidity and complication rates, (if any), associated with the use of the Needle Guide.1 week

Secondary

MeasureTime frame
to evaluate the comparative ease of the injection procedure using the Bulking Agent Needle Guide as compared to the traditional transurethral or periurethral injection technique.at procedure

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026